方法证据记录
Bayesian Phase I clinical trial
A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.
源记录
引文逐字复制自方法源记录。这些引文不代表任何层级的验证。
Bayesian Phase I Clinical Trial (Dose-Finding Design)
分类方法记录 · process-pipeline / epidemiology
- O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. · DOI 10.2307/2531628
- Chevret, S. (Ed.). (2006). Statistical Methods for Dose-Finding Experiments. Wiley. · ISBN 978-0470861769
精选声明
声明已持久化到证据分类账中，每个声明都有自己的评估。
尚无精选声明
当分类账中没有声明时，此视图不会自行创建声明评估。
相关方法
从方法图中生成，显示为机器建议的关系 — 不推断任何证据声明。